http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 09 Sep 2026 06:02:09 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/New+Coverage/Oppenheimer+Starts+Aktis+Oncology+%28AKTS%29+at+Outperform/27038516.html <p>Oppenheimer analyst Jeff Jones initiates coverage on Aktis Oncology (NASDAQ: AKTS) with a Outperform rating and a price target of $40.00.</p><p>The analyst comments "We are initiating coverage of AKTS, a leader in the targeted radiopharmaceutical (TRP) space, with an Outperform rating and $40 PT. Our thesis is driven by our enthusiasm for AKTS' miniprotein conjugate platform and two clinical-stage targeted radiopharmaceutical (TRP) candidates AKY-1189 and AKY-2519, addressing validated targets with applications in multiple blockbuster opportunities. We anticipate key clinical updates for each candidate next year, including efficacy updates in both mCRPC and mUC and other solid tumors. Both AKY-1189 and http://www.streetinsider.com/New+Coverage/Oppenheimer+Starts+Aktis+Oncology+%28AKTS%29+at+Outperform/27038516.html Wed, 09 Sep 2026 06:02:09 -0400 AKTS http://www.streetinsider.com/Analyst+Comments/Oppenheimer+Starts+Aktis+Oncology+%28AKTS%29+at+Outperform/27038516.html <p>Oppenheimer analyst Jeff Jones initiates coverage on Aktis Oncology (NASDAQ: AKTS) with a Outperform rating and a price target of $40.00.</p><p>The analyst comments "We are initiating coverage of AKTS, a leader in the targeted radiopharmaceutical (TRP) space, with an Outperform rating and $40 PT. Our thesis is driven by our enthusiasm for AKTS' miniprotein conjugate platform and two clinical-stage targeted radiopharmaceutical (TRP) candidates AKY-1189 and AKY-2519, addressing validated targets with applications in multiple blockbuster opportunities. We anticipate key clinical updates for each candidate next year, including efficacy updates in both mCRPC and mUC and other solid tumors. Both AKY-1189 and http://www.streetinsider.com/Analyst+Comments/Oppenheimer+Starts+Aktis+Oncology+%28AKTS%29+at+Outperform/27038516.html Wed, 09 Sep 2026 06:02:09 -0400 AKTS http://www.streetinsider.com/New+Coverage/Wedbush+Starts+Aktis+Oncology+%28AKTS%29+at+Outperform/26947015.html (Updated - August 19, 2026 7:00 AM EDT) <p>Wedbush analyst David Nierengarten initiates coverage on Aktis Oncology (NASDAQ: AKTS) with a Outperform rating and a price target of $35.00.</p><p>The analyst comments "We are initiating coverage of AKTS with an OUTPERFORM rating and a $35 price target. AKTS is a compelling pure-play radiopharma story targeting two clinically validated solid tumor antigens with limited direct radioconjugate competition. AKTS is developing 225Ac miniprotein radioconjugates designed to combine antibody-like target binding with peptide-like tumor penetration and rapid systemic clearance, potentially improving safety and efficacy. Lead asset AKY-1189 targets Nectin-4, the commercially validated antigen behind Padcev, http://www.streetinsider.com/New+Coverage/Wedbush+Starts+Aktis+Oncology+%28AKTS%29+at+Outperform/26947015.html Wed, 19 Aug 2026 07:00:05 -0400 AKTS http://www.streetinsider.com/Analyst+Comments/Wedbush+Starts+Aktis+Oncology+%28AKTS%29+at+Outperform/26947015.html (Updated - August 19, 2026 7:00 AM EDT) <p>Wedbush analyst David Nierengarten initiates coverage on Aktis Oncology (NASDAQ: AKTS) with a Outperform rating and a price target of $35.00.</p><p>The analyst comments "We are initiating coverage of AKTS with an OUTPERFORM rating and a $35 price target. AKTS is a compelling pure-play radiopharma story targeting two clinically validated solid tumor antigens with limited direct radioconjugate competition. AKTS is developing 225Ac miniprotein radioconjugates designed to combine antibody-like target binding with peptide-like tumor penetration and rapid systemic clearance, potentially improving safety and efficacy. Lead asset AKY-1189 targets Nectin-4, the commercially validated antigen behind Padcev, http://www.streetinsider.com/Analyst+Comments/Wedbush+Starts+Aktis+Oncology+%28AKTS%29+at+Outperform/26947015.html Wed, 19 Aug 2026 07:00:05 -0400 AKTS http://www.streetinsider.com/Hot+Comments/Wedbush+Starts+Aktis+Oncology+%28AKTS%29+at+Outperform/26947015.html (Updated - August 19, 2026 7:00 AM EDT) <p>Wedbush analyst David Nierengarten initiates coverage on Aktis Oncology (NASDAQ: AKTS) with a Outperform rating and a price target of $35.00.</p><p>The analyst comments "We are initiating coverage of AKTS with an OUTPERFORM rating and a $35 price target. AKTS is a compelling pure-play radiopharma story targeting two clinically validated solid tumor antigens with limited direct radioconjugate competition. AKTS is developing 225Ac miniprotein radioconjugates designed to combine antibody-like target binding with peptide-like tumor penetration and rapid systemic clearance, potentially improving safety and efficacy. Lead asset AKY-1189 targets Nectin-4, the commercially validated antigen behind Padcev, http://www.streetinsider.com/Hot+Comments/Wedbush+Starts+Aktis+Oncology+%28AKTS%29+at+Outperform/26947015.html Wed, 19 Aug 2026 07:00:05 -0400 AKTS http://www.streetinsider.com/Hot+New+Coverage/Wedbush+Starts+Aktis+Oncology+%28AKTS%29+at+Outperform/26947015.html (Updated - August 19, 2026 7:00 AM EDT) <p>Wedbush analyst David Nierengarten initiates coverage on Aktis Oncology (NASDAQ: AKTS) with a Outperform rating and a price target of $35.00.</p><p>The analyst comments "We are initiating coverage of AKTS with an OUTPERFORM rating and a $35 price target. AKTS is a compelling pure-play radiopharma story targeting two clinically validated solid tumor antigens with limited direct radioconjugate competition. AKTS is developing 225Ac miniprotein radioconjugates designed to combine antibody-like target binding with peptide-like tumor penetration and rapid systemic clearance, potentially improving safety and efficacy. Lead asset AKY-1189 targets Nectin-4, the commercially validated antigen behind Padcev, http://www.streetinsider.com/Hot+New+Coverage/Wedbush+Starts+Aktis+Oncology+%28AKTS%29+at+Outperform/26947015.html Wed, 19 Aug 2026 07:00:05 -0400 AKTS http://www.streetinsider.com/New+Coverage/BMO+Capital+Starts+Aktis+Oncology+%28AKTS%29+at+Outperform/26944373.html (Updated - August 19, 2026 5:30 AM EDT) <p>BMO Capital analyst David Lebowitz initiates coverage on Aktis Oncology (NASDAQ: AKTS) with a Outperform rating, PT $37.00.</p><p>The analyst comments "We initiate coverage of Aktis Oncology (AKTS) with an Outperform rating and a $37 target price. Aktis is developing differentiated precision radioligand therapies using its proprietary platform of Actinium-225-conjugated miniproteins. Targeting large markets across Nectin-4- and B7-H3-expressing solid tumors, Aktis’s lead assets leverage clinically-validated target biology and could deliver superior efficacy relative to competing therapies. Supported by compelling preclinical and initial human imaging data, we see significant commercial potential for both lead assets http://www.streetinsider.com/New+Coverage/BMO+Capital+Starts+Aktis+Oncology+%28AKTS%29+at+Outperform/26944373.html Wed, 19 Aug 2026 05:30:29 -0400 AKTS http://www.streetinsider.com/Analyst+Comments/BMO+Capital+Starts+Aktis+Oncology+%28AKTS%29+at+Outperform/26944373.html (Updated - August 19, 2026 5:30 AM EDT) <p>BMO Capital analyst David Lebowitz initiates coverage on Aktis Oncology (NASDAQ: AKTS) with a Outperform rating, PT $37.00.</p><p>The analyst comments "We initiate coverage of Aktis Oncology (AKTS) with an Outperform rating and a $37 target price. Aktis is developing differentiated precision radioligand therapies using its proprietary platform of Actinium-225-conjugated miniproteins. Targeting large markets across Nectin-4- and B7-H3-expressing solid tumors, Aktis’s lead assets leverage clinically-validated target biology and could deliver superior efficacy relative to competing therapies. Supported by compelling preclinical and initial human imaging data, we see significant commercial potential for both lead assets http://www.streetinsider.com/Analyst+Comments/BMO+Capital+Starts+Aktis+Oncology+%28AKTS%29+at+Outperform/26944373.html Wed, 19 Aug 2026 05:30:29 -0400 AKTS http://www.streetinsider.com/Press+Releases/Aktis+Oncology+Reports+Financial+Results+and+Business+Highlights+for+the+Second+Quarter+2026/26920498.html <ul type="disc"><li>Presented first-in-human clinical imaging and dosimetry data for AKY-2519, supporting a broad clinical development program in patients with prostate, lung, and other B7-H3 expressing solid tumors</li><li>Enrolling patients in Phase 1b trial of AKY-1189 in locally advanced or metastatic urothelial cancer (mUC) and other Nectin-4 expressing solid tumors</li><li>Initiated Phase 1b trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC)</li><li>On track to initiate Phase 1b trial of AKY-2519 in other B7-H3 expressing solid tumors, including lung cancers, in the second half of 2026</li></ul> <p>BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (“Aktis” or the “Company”), http://www.streetinsider.com/Press+Releases/Aktis+Oncology+Reports+Financial+Results+and+Business+Highlights+for+the+Second+Quarter+2026/26920498.html Thu, 13 Aug 2026 16:01:00 -0400 AKTS http://www.streetinsider.com/Globe+Newswire/Aktis+Oncology+Reports+Financial+Results+and+Business+Highlights+for+the+Second+Quarter+2026/26920498.html <ul type="disc"><li>Presented first-in-human clinical imaging and dosimetry data for AKY-2519, supporting a broad clinical development program in patients with prostate, lung, and other B7-H3 expressing solid tumors</li><li>Enrolling patients in Phase 1b trial of AKY-1189 in locally advanced or metastatic urothelial cancer (mUC) and other Nectin-4 expressing solid tumors</li><li>Initiated Phase 1b trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC)</li><li>On track to initiate Phase 1b trial of AKY-2519 in other B7-H3 expressing solid tumors, including lung cancers, in the second half of 2026</li></ul> <p>BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (“Aktis” or the “Company”), http://www.streetinsider.com/Globe+Newswire/Aktis+Oncology+Reports+Financial+Results+and+Business+Highlights+for+the+Second+Quarter+2026/26920498.html Thu, 13 Aug 2026 16:01:00 -0400 AKTS http://www.streetinsider.com/New+Coverage/Leerink+Assumes+Aktis+Oncology+%28AKTS%29+at+Outperform/26796278.html <p>Leerink analyst Asthika Goonewardene assumes coverage on Aktis Oncology (NASDAQ: AKTS) with a Outperform rating and a price target of $33.00.</p> <p>For an analyst ratings summary and ratings history on Aktis Oncology <a href="http://www.streetinsider.com/rating_history.php?q=AKTS">click here</a>. For more ratings news on Aktis Oncology <a href="http://www.streetinsider.com/stock_lookup_news.php?q=AKTS&amp;type=analyst">click here</a>.</p> <p>Shares of Aktis Oncology closed at $23.96 yesterday.</p> http://www.streetinsider.com/New+Coverage/Leerink+Assumes+Aktis+Oncology+%28AKTS%29+at+Outperform/26796278.html Tue, 21 Jul 2026 16:49:37 -0400 AKTS http://www.streetinsider.com/Analyst+PT+Change/Aktis+Oncology+%28AKTS%29+PT+Raised+to+%2433+at+JPMorgan/26764881.html JPMorgan analyst Jessica Fye raised the price target on Aktis Oncology (NASDAQ: AKTS) to $33.00 (from $30.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Aktis+Oncology+%28AKTS%29+PT+Raised+to+%2433+at+JPMorgan/26764881.html Tue, 14 Jul 2026 07:42:20 -0400 AKTS http://www.streetinsider.com/Hot+New+Coverage/Raymond+James+Starts+Aktis+Oncology+%28AKTS%29+at+Strong+Buy+%28correction%29/26647360.html (Updated - June 15, 2026 4:09 PM EDT) <p>Raymond James analyst Chris Raymond initiates coverage on Aktis Oncology (NASDAQ: AKTS) with a Strong Buy rating and a price target of $40.00.</p><p>The analyst comments "We are initiating coverage of AKTS shares with a Strong Buy rating and $40 price target. With the targeted radiopharma field growing rapidly, we believe a strongly differentiated approach in the space is ideally poised to command investor attention. To that end, we think Aktis’s miniprotein-enabled radioligand therapy (RLT) platform is highly differentiated, potentially offering better efficacy, safety, and developmental flexibility than earlier generation radiotherapy approaches. Miniproteins are http://www.streetinsider.com/Hot+New+Coverage/Raymond+James+Starts+Aktis+Oncology+%28AKTS%29+at+Strong+Buy+%28correction%29/26647360.html Mon, 15 Jun 2026 16:09:21 -0400 AKTS LLY http://www.streetinsider.com/Hot+New+Coverage/Raymond+James+Starts+Aktis+Oncology+%28AKTS%29+at+Strong+Buy+%28correction%29/26647360.html (Updated - June 15, 2026 4:09 PM EDT) <p>Raymond James analyst Chris Raymond initiates coverage on Aktis Oncology (NASDAQ: AKTS) with a Strong Buy rating and a price target of $40.00.</p><p>The analyst comments "We are initiating coverage of AKTS shares with a Strong Buy rating and $40 price target. With the targeted radiopharma field growing rapidly, we believe a strongly differentiated approach in the space is ideally poised to command investor attention. To that end, we think Aktis’s miniprotein-enabled radioligand therapy (RLT) platform is highly differentiated, potentially offering better efficacy, safety, and developmental flexibility than earlier generation radiotherapy approaches. Miniproteins are http://www.streetinsider.com/Hot+New+Coverage/Raymond+James+Starts+Aktis+Oncology+%28AKTS%29+at+Strong+Buy+%28correction%29/26647360.html Mon, 15 Jun 2026 16:09:21 -0400 AKTS LLY http://www.streetinsider.com/New+Coverage/Raymond+James+Starts+Aktis+Oncology+%28AKTS%29+at+Strong+Buy+%28correction%29/26647360.html (Updated - June 15, 2026 4:09 PM EDT) <p>Raymond James analyst Chris Raymond initiates coverage on Aktis Oncology (NASDAQ: AKTS) with a Strong Buy rating and a price target of $40.00.</p><p>The analyst comments "We are initiating coverage of AKTS shares with a Strong Buy rating and $40 price target. With the targeted radiopharma field growing rapidly, we believe a strongly differentiated approach in the space is ideally poised to command investor attention. To that end, we think Aktis’s miniprotein-enabled radioligand therapy (RLT) platform is highly differentiated, potentially offering better efficacy, safety, and developmental flexibility than earlier generation radiotherapy approaches. Miniproteins are http://www.streetinsider.com/New+Coverage/Raymond+James+Starts+Aktis+Oncology+%28AKTS%29+at+Strong+Buy+%28correction%29/26647360.html Mon, 15 Jun 2026 16:09:21 -0400 AKTS LLY http://www.streetinsider.com/New+Coverage/Raymond+James+Starts+Aktis+Oncology+%28AKTS%29+at+Strong+Buy+%28correction%29/26647360.html (Updated - June 15, 2026 4:09 PM EDT) <p>Raymond James analyst Chris Raymond initiates coverage on Aktis Oncology (NASDAQ: AKTS) with a Strong Buy rating and a price target of $40.00.</p><p>The analyst comments "We are initiating coverage of AKTS shares with a Strong Buy rating and $40 price target. With the targeted radiopharma field growing rapidly, we believe a strongly differentiated approach in the space is ideally poised to command investor attention. To that end, we think Aktis’s miniprotein-enabled radioligand therapy (RLT) platform is highly differentiated, potentially offering better efficacy, safety, and developmental flexibility than earlier generation radiotherapy approaches. Miniproteins are http://www.streetinsider.com/New+Coverage/Raymond+James+Starts+Aktis+Oncology+%28AKTS%29+at+Strong+Buy+%28correction%29/26647360.html Mon, 15 Jun 2026 16:09:21 -0400 AKTS LLY http://www.streetinsider.com/Analyst+Comments/Raymond+James+Starts+Aktis+Oncology+%28AKTS%29+at+Strong+Buy+%28correction%29/26647360.html (Updated - June 15, 2026 4:09 PM EDT) <p>Raymond James analyst Chris Raymond initiates coverage on Aktis Oncology (NASDAQ: AKTS) with a Strong Buy rating and a price target of $40.00.</p><p>The analyst comments "We are initiating coverage of AKTS shares with a Strong Buy rating and $40 price target. With the targeted radiopharma field growing rapidly, we believe a strongly differentiated approach in the space is ideally poised to command investor attention. To that end, we think Aktis’s miniprotein-enabled radioligand therapy (RLT) platform is highly differentiated, potentially offering better efficacy, safety, and developmental flexibility than earlier generation radiotherapy approaches. Miniproteins are http://www.streetinsider.com/Analyst+Comments/Raymond+James+Starts+Aktis+Oncology+%28AKTS%29+at+Strong+Buy+%28correction%29/26647360.html Mon, 15 Jun 2026 16:09:21 -0400 AKTS LLY http://www.streetinsider.com/Analyst+Comments/Raymond+James+Starts+Aktis+Oncology+%28AKTS%29+at+Strong+Buy+%28correction%29/26647360.html (Updated - June 15, 2026 4:09 PM EDT) <p>Raymond James analyst Chris Raymond initiates coverage on Aktis Oncology (NASDAQ: AKTS) with a Strong Buy rating and a price target of $40.00.</p><p>The analyst comments "We are initiating coverage of AKTS shares with a Strong Buy rating and $40 price target. With the targeted radiopharma field growing rapidly, we believe a strongly differentiated approach in the space is ideally poised to command investor attention. To that end, we think Aktis’s miniprotein-enabled radioligand therapy (RLT) platform is highly differentiated, potentially offering better efficacy, safety, and developmental flexibility than earlier generation radiotherapy approaches. Miniproteins are http://www.streetinsider.com/Analyst+Comments/Raymond+James+Starts+Aktis+Oncology+%28AKTS%29+at+Strong+Buy+%28correction%29/26647360.html Mon, 15 Jun 2026 16:09:21 -0400 AKTS LLY http://www.streetinsider.com/Hot+Comments/Raymond+James+Starts+Aktis+Oncology+%28AKTS%29+at+Strong+Buy+%28correction%29/26647360.html (Updated - June 15, 2026 4:09 PM EDT) <p>Raymond James analyst Chris Raymond initiates coverage on Aktis Oncology (NASDAQ: AKTS) with a Strong Buy rating and a price target of $40.00.</p><p>The analyst comments "We are initiating coverage of AKTS shares with a Strong Buy rating and $40 price target. With the targeted radiopharma field growing rapidly, we believe a strongly differentiated approach in the space is ideally poised to command investor attention. To that end, we think Aktis’s miniprotein-enabled radioligand therapy (RLT) platform is highly differentiated, potentially offering better efficacy, safety, and developmental flexibility than earlier generation radiotherapy approaches. Miniproteins are http://www.streetinsider.com/Hot+Comments/Raymond+James+Starts+Aktis+Oncology+%28AKTS%29+at+Strong+Buy+%28correction%29/26647360.html Mon, 15 Jun 2026 16:09:21 -0400 AKTS LLY http://www.streetinsider.com/Hot+Comments/Raymond+James+Starts+Aktis+Oncology+%28AKTS%29+at+Strong+Buy+%28correction%29/26647360.html (Updated - June 15, 2026 4:09 PM EDT) <p>Raymond James analyst Chris Raymond initiates coverage on Aktis Oncology (NASDAQ: AKTS) with a Strong Buy rating and a price target of $40.00.</p><p>The analyst comments "We are initiating coverage of AKTS shares with a Strong Buy rating and $40 price target. With the targeted radiopharma field growing rapidly, we believe a strongly differentiated approach in the space is ideally poised to command investor attention. To that end, we think Aktis’s miniprotein-enabled radioligand therapy (RLT) platform is highly differentiated, potentially offering better efficacy, safety, and developmental flexibility than earlier generation radiotherapy approaches. Miniproteins are http://www.streetinsider.com/Hot+Comments/Raymond+James+Starts+Aktis+Oncology+%28AKTS%29+at+Strong+Buy+%28correction%29/26647360.html Mon, 15 Jun 2026 16:09:21 -0400 AKTS LLY http://www.streetinsider.com/Analyst+PT+Change/Akoustis+Technologies+%28AKTS%29+PT+Raised+to+%2435+at+H.C.+Wainwright/26595097.html (Updated - June 3, 2026 6:50 AM EDT) <p>H.C. Wainwright analyst Robert Burns raised the price target on Akoustis Technologies (NASDAQ: AKTS) to $35.00 (from $33.00) while maintaining a Buy rating.</p><p>The analyst commented: "At ASCO 2026, Aktis Oncology presented biodistribution and dosimetry results for AKY-2519. As shown in the two posters, AKY-2519's uptake in critical normal tissues is well below the normal-tissue dose limit thresholds (see Figure 1 below and Figure 3 overleaf); notably, the low predicted absorbed dose to salivary glands may differentiate an AKY-2519 RCT from other PSMA-targeted agents. The compound also displayed robust uptake and retention in a http://www.streetinsider.com/Analyst+PT+Change/Akoustis+Technologies+%28AKTS%29+PT+Raised+to+%2435+at+H.C.+Wainwright/26595097.html Wed, 03 Jun 2026 06:50:41 -0400 AKTS http://www.streetinsider.com/Analyst+Comments/Akoustis+Technologies+%28AKTS%29+PT+Raised+to+%2435+at+H.C.+Wainwright/26595097.html (Updated - June 3, 2026 6:50 AM EDT) <p>H.C. Wainwright analyst Robert Burns raised the price target on Akoustis Technologies (NASDAQ: AKTS) to $35.00 (from $33.00) while maintaining a Buy rating.</p><p>The analyst commented: "At ASCO 2026, Aktis Oncology presented biodistribution and dosimetry results for AKY-2519. As shown in the two posters, AKY-2519's uptake in critical normal tissues is well below the normal-tissue dose limit thresholds (see Figure 1 below and Figure 3 overleaf); notably, the low predicted absorbed dose to salivary glands may differentiate an AKY-2519 RCT from other PSMA-targeted agents. The compound also displayed robust uptake and retention in a http://www.streetinsider.com/Analyst+Comments/Akoustis+Technologies+%28AKTS%29+PT+Raised+to+%2435+at+H.C.+Wainwright/26595097.html Wed, 03 Jun 2026 06:50:41 -0400 AKTS http://www.streetinsider.com/Press+Releases/Aktis+Oncology+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26557695.html <p>BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the Jefferies Global Healthcare Conference in New York, New York. The presentation will take place on Wednesday, June 3, 2026, at 4:20 p.m. ET.</p> <p>A live webcast of the presentations may be accessed via the Investors section of the Aktis website at <a http://www.streetinsider.com/Press+Releases/Aktis+Oncology+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26557695.html Wed, 27 May 2026 16:05:00 -0400 AKTS http://www.streetinsider.com/Globe+Newswire/Aktis+Oncology+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26557695.html <p>BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the Jefferies Global Healthcare Conference in New York, New York. The presentation will take place on Wednesday, June 3, 2026, at 4:20 p.m. ET.</p> <p>A live webcast of the presentations may be accessed via the Investors section of the Aktis website at <a http://www.streetinsider.com/Globe+Newswire/Aktis+Oncology+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26557695.html Wed, 27 May 2026 16:05:00 -0400 AKTS http://www.streetinsider.com/Corporate+News/Aktis+reports+imaging+data+for+cancer+drug+targeting+B7-H3+protein/26537023.html <p>Aktis Oncology Inc. (NASDAQ: AKTS) released first-in-human clinical imaging and dosimetry data for AKY-2519, a radioconjugate targeting B7-H3 expressing tumors. The data will be presented at the 2026 American Society of Clinical Oncology Annual Meeting from May 29 to June 2 in Chicago.</p><p>Two separate assessments evaluated AKY-2519 in patients with metastatic castration-resistant prostate cancer and various solid tumor types. The studies demonstrated tumor uptake and normal tissue exposure levels, according to the company's statement.</p><p>The first assessment, conducted at the University of Pretoria and Steve Biko Academic Hospital in South Africa, evaluated 16 patients with metastatic castration-resistant prostate cancer. Patients received http://www.streetinsider.com/Corporate+News/Aktis+reports+imaging+data+for+cancer+drug+targeting+B7-H3+protein/26537023.html Thu, 21 May 2026 17:36:37 -0400 AKTS